12/18
09:19 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/18
07:09 am
agio
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease [Yahoo! Finance]
Medium
Report
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease [Yahoo! Finance]
12/18
07:00 am
agio
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Medium
Report
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
12/10
10:20 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $55.00 to $57.00. They now have an "outperform" rating on the stock.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $55.00 to $57.00. They now have an "outperform" rating on the stock.
12/9
10:55 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $53.00 to $75.00. They now have a "sector outperform" rating on the stock.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $53.00 to $75.00. They now have a "sector outperform" rating on the stock.
12/8
12:47 pm
agio
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat [Yahoo! Finance]
High
Report
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat [Yahoo! Finance]
12/8
12:40 pm
agio
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
High
Report
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
12/5
10:20 am
agio
TruePKU Initiative Provides Global PKU Community an Opportunity to Share What It's Like to Live with PKU [Yahoo! Finance]
Low
Report
TruePKU Initiative Provides Global PKU Community an Opportunity to Share What It's Like to Live with PKU [Yahoo! Finance]
12/5
06:42 am
agio
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios [Yahoo! Finance]
Low
Report
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios [Yahoo! Finance]
11/26
10:59 am
agio
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
11/9
02:07 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/7
07:18 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News [Yahoo! Finance]
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News [Yahoo! Finance]
11/5
09:11 am
agio
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
Medium
Report
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
11/5
09:05 am
agio
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Medium
Report
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
11/1
11:06 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/1
12:38 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
11/1
10:34 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $51.00 to $53.00. They now have a "sector outperform" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Scotiabank from $51.00 to $53.00. They now have a "sector outperform" rating on the stock.
11/1
09:18 am
agio
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
10/31
06:30 am
agio
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
Medium
Report
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
10/23
07:00 am
agio
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
Low
Report
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
10/17
07:00 am
agio
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
Low
Report
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
10/16
11:05 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/16
08:44 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/10
09:36 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
9/28
07:43 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.